Accordingly, it revealed that SGLT2 inhibitors vs. placebo significantly reduced the composite HF outcome regardless of these four factors, while SGLT2 inhibitors might yield more reductions in that outcome in patients with HF living in Asia, Asian and Black patients with HF, and HF patients with NYHA class II. Here, SLC5A2 is linked to hydrops fetalis.